A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.
Identifieur interne : 001468 ( PubMed/Corpus ); précédent : 001467; suivant : 001469A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.
Auteurs : Meagan Bolles ; Damon Deming ; Kristin Long ; Sudhakar Agnihothram ; Alan Whitmore ; Martin Ferris ; William Funkhouser ; Lisa Gralinski ; Allison Totura ; Mark Heise ; Ralph S. BaricSource :
- Journal of virology [ 1098-5514 ] ; 2011.
English descriptors
- KwdEn :
- Animals, Antibodies, Viral (immunology), Blotting, Western, Chlorocebus aethiops, Enzyme-Linked Immunosorbent Assay, Female, Lung (immunology), Lung (pathology), Lung (virology), Mice, Mice, Inbred BALB C, Neutralization Tests, Pulmonary Eosinophilia (immunology), Pulmonary Eosinophilia (pathology), Pulmonary Eosinophilia (virology), RNA, Messenger (genetics), Real-Time Polymerase Chain Reaction, SARS Virus (genetics), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology), Vaccination, Vaccines, Inactivated (therapeutic use), Vero Cells, Viral Envelope Proteins (genetics), Viral Envelope Proteins (metabolism), Viral Vaccines (therapeutic use).
- MESH :
- chemical , genetics : RNA, Messenger, Viral Envelope Proteins.
- chemical , immunology : Antibodies, Viral.
- genetics : SARS Virus.
- immunology : Lung, Pulmonary Eosinophilia, SARS Virus, Severe Acute Respiratory Syndrome.
- chemical , metabolism : Viral Envelope Proteins.
- pathology : Lung, Pulmonary Eosinophilia.
- prevention & control : Severe Acute Respiratory Syndrome.
- chemical , therapeutic use : Vaccines, Inactivated, Viral Vaccines.
- virology : Lung, Pulmonary Eosinophilia, Severe Acute Respiratory Syndrome.
- Animals, Blotting, Western, Chlorocebus aethiops, Enzyme-Linked Immunosorbent Assay, Female, Mice, Mice, Inbred BALB C, Neutralization Tests, Real-Time Polymerase Chain Reaction, Vaccination, Vero Cells.
Abstract
Severe acute respiratory syndrome coronavirus (SARS-CoV) is an important emerging virus that is highly pathogenic in aged populations and is maintained with great diversity in zoonotic reservoirs. While a variety of vaccine platforms have shown efficacy in young-animal models and against homologous viral strains, vaccine efficacy has not been thoroughly evaluated using highly pathogenic variants that replicate the acute end stage lung disease phenotypes seen during the human epidemic. Using an adjuvanted and an unadjuvanted double-inactivated SARS-CoV (DIV) vaccine, we demonstrate an eosinophilic immunopathology in aged mice comparable to that seen in mice immunized with the SARS nucleocapsid protein, and poor protection against a nonlethal heterologous challenge. In young and 1-year-old animals, we demonstrate that adjuvanted DIV vaccine provides protection against lethal disease in young animals following homologous and heterologous challenge, although enhanced immune pathology and eosinophilia are evident following heterologous challenge. In the absence of alum, DIV vaccine performed poorly in young animals challenged with lethal homologous or heterologous strains. In contrast, DIV vaccines (both adjuvanted and unadjuvanted) performed poorly in aged-animal models. Importantly, aged animals displayed increased eosinophilic immune pathology in the lungs and were not protected against significant virus replication. These data raise significant concerns regarding DIV vaccine safety and highlight the need for additional studies of the molecular mechanisms governing DIV-induced eosinophilia and vaccine failure, especially in the more vulnerable aged-animal models of human disease.
DOI: 10.1128/JVI.06048-11
PubMed: 21937658
Links to Exploration step
pubmed:21937658Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.</title><author><name sortKey="Bolles, Meagan" sort="Bolles, Meagan" uniqKey="Bolles M" first="Meagan" last="Bolles">Meagan Bolles</name><affiliation><nlm:affiliation>Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Deming, Damon" sort="Deming, Damon" uniqKey="Deming D" first="Damon" last="Deming">Damon Deming</name></author><author><name sortKey="Long, Kristin" sort="Long, Kristin" uniqKey="Long K" first="Kristin" last="Long">Kristin Long</name></author><author><name sortKey="Agnihothram, Sudhakar" sort="Agnihothram, Sudhakar" uniqKey="Agnihothram S" first="Sudhakar" last="Agnihothram">Sudhakar Agnihothram</name></author><author><name sortKey="Whitmore, Alan" sort="Whitmore, Alan" uniqKey="Whitmore A" first="Alan" last="Whitmore">Alan Whitmore</name></author><author><name sortKey="Ferris, Martin" sort="Ferris, Martin" uniqKey="Ferris M" first="Martin" last="Ferris">Martin Ferris</name></author><author><name sortKey="Funkhouser, William" sort="Funkhouser, William" uniqKey="Funkhouser W" first="William" last="Funkhouser">William Funkhouser</name></author><author><name sortKey="Gralinski, Lisa" sort="Gralinski, Lisa" uniqKey="Gralinski L" first="Lisa" last="Gralinski">Lisa Gralinski</name></author><author><name sortKey="Totura, Allison" sort="Totura, Allison" uniqKey="Totura A" first="Allison" last="Totura">Allison Totura</name></author><author><name sortKey="Heise, Mark" sort="Heise, Mark" uniqKey="Heise M" first="Mark" last="Heise">Mark Heise</name></author><author><name sortKey="Baric, Ralph S" sort="Baric, Ralph S" uniqKey="Baric R" first="Ralph S" last="Baric">Ralph S. Baric</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21937658</idno><idno type="pmid">21937658</idno><idno type="doi">10.1128/JVI.06048-11</idno><idno type="wicri:Area/PubMed/Corpus">001468</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001468</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.</title><author><name sortKey="Bolles, Meagan" sort="Bolles, Meagan" uniqKey="Bolles M" first="Meagan" last="Bolles">Meagan Bolles</name><affiliation><nlm:affiliation>Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Deming, Damon" sort="Deming, Damon" uniqKey="Deming D" first="Damon" last="Deming">Damon Deming</name></author><author><name sortKey="Long, Kristin" sort="Long, Kristin" uniqKey="Long K" first="Kristin" last="Long">Kristin Long</name></author><author><name sortKey="Agnihothram, Sudhakar" sort="Agnihothram, Sudhakar" uniqKey="Agnihothram S" first="Sudhakar" last="Agnihothram">Sudhakar Agnihothram</name></author><author><name sortKey="Whitmore, Alan" sort="Whitmore, Alan" uniqKey="Whitmore A" first="Alan" last="Whitmore">Alan Whitmore</name></author><author><name sortKey="Ferris, Martin" sort="Ferris, Martin" uniqKey="Ferris M" first="Martin" last="Ferris">Martin Ferris</name></author><author><name sortKey="Funkhouser, William" sort="Funkhouser, William" uniqKey="Funkhouser W" first="William" last="Funkhouser">William Funkhouser</name></author><author><name sortKey="Gralinski, Lisa" sort="Gralinski, Lisa" uniqKey="Gralinski L" first="Lisa" last="Gralinski">Lisa Gralinski</name></author><author><name sortKey="Totura, Allison" sort="Totura, Allison" uniqKey="Totura A" first="Allison" last="Totura">Allison Totura</name></author><author><name sortKey="Heise, Mark" sort="Heise, Mark" uniqKey="Heise M" first="Mark" last="Heise">Mark Heise</name></author><author><name sortKey="Baric, Ralph S" sort="Baric, Ralph S" uniqKey="Baric R" first="Ralph S" last="Baric">Ralph S. Baric</name></author></analytic><series><title level="j">Journal of virology</title><idno type="eISSN">1098-5514</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Viral (immunology)</term><term>Blotting, Western</term><term>Chlorocebus aethiops</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Female</term><term>Lung (immunology)</term><term>Lung (pathology)</term><term>Lung (virology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests</term><term>Pulmonary Eosinophilia (immunology)</term><term>Pulmonary Eosinophilia (pathology)</term><term>Pulmonary Eosinophilia (virology)</term><term>RNA, Messenger (genetics)</term><term>Real-Time Polymerase Chain Reaction</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Vaccination</term><term>Vaccines, Inactivated (therapeutic use)</term><term>Vero Cells</term><term>Viral Envelope Proteins (genetics)</term><term>Viral Envelope Proteins (metabolism)</term><term>Viral Vaccines (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>RNA, Messenger</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Lung</term><term>Pulmonary Eosinophilia</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung</term><term>Pulmonary Eosinophilia</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term><term>Pulmonary Eosinophilia</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Blotting, Western</term><term>Chlorocebus aethiops</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Female</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests</term><term>Real-Time Polymerase Chain Reaction</term><term>Vaccination</term><term>Vero Cells</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome coronavirus (SARS-CoV) is an important emerging virus that is highly pathogenic in aged populations and is maintained with great diversity in zoonotic reservoirs. While a variety of vaccine platforms have shown efficacy in young-animal models and against homologous viral strains, vaccine efficacy has not been thoroughly evaluated using highly pathogenic variants that replicate the acute end stage lung disease phenotypes seen during the human epidemic. Using an adjuvanted and an unadjuvanted double-inactivated SARS-CoV (DIV) vaccine, we demonstrate an eosinophilic immunopathology in aged mice comparable to that seen in mice immunized with the SARS nucleocapsid protein, and poor protection against a nonlethal heterologous challenge. In young and 1-year-old animals, we demonstrate that adjuvanted DIV vaccine provides protection against lethal disease in young animals following homologous and heterologous challenge, although enhanced immune pathology and eosinophilia are evident following heterologous challenge. In the absence of alum, DIV vaccine performed poorly in young animals challenged with lethal homologous or heterologous strains. In contrast, DIV vaccines (both adjuvanted and unadjuvanted) performed poorly in aged-animal models. Importantly, aged animals displayed increased eosinophilic immune pathology in the lungs and were not protected against significant virus replication. These data raise significant concerns regarding DIV vaccine safety and highlight the need for additional studies of the molecular mechanisms governing DIV-induced eosinophilia and vaccine failure, especially in the more vulnerable aged-animal models of human disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21937658</PMID><DateCompleted><Year>2012</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>23</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J. Virol.</ISOAbbreviation></Journal><ArticleTitle>A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.</ArticleTitle><Pagination><MedlinePgn>12201-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.06048-11</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus (SARS-CoV) is an important emerging virus that is highly pathogenic in aged populations and is maintained with great diversity in zoonotic reservoirs. While a variety of vaccine platforms have shown efficacy in young-animal models and against homologous viral strains, vaccine efficacy has not been thoroughly evaluated using highly pathogenic variants that replicate the acute end stage lung disease phenotypes seen during the human epidemic. Using an adjuvanted and an unadjuvanted double-inactivated SARS-CoV (DIV) vaccine, we demonstrate an eosinophilic immunopathology in aged mice comparable to that seen in mice immunized with the SARS nucleocapsid protein, and poor protection against a nonlethal heterologous challenge. In young and 1-year-old animals, we demonstrate that adjuvanted DIV vaccine provides protection against lethal disease in young animals following homologous and heterologous challenge, although enhanced immune pathology and eosinophilia are evident following heterologous challenge. In the absence of alum, DIV vaccine performed poorly in young animals challenged with lethal homologous or heterologous strains. In contrast, DIV vaccines (both adjuvanted and unadjuvanted) performed poorly in aged-animal models. Importantly, aged animals displayed increased eosinophilic immune pathology in the lungs and were not protected against significant virus replication. These data raise significant concerns regarding DIV vaccine safety and highlight the need for additional studies of the molecular mechanisms governing DIV-induced eosinophilia and vaccine failure, especially in the more vulnerable aged-animal models of human disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bolles</LastName><ForeName>Meagan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deming</LastName><ForeName>Damon</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Agnihothram</LastName><ForeName>Sudhakar</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Whitmore</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ferris</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Funkhouser</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Gralinski</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Totura</LastName><ForeName>Allison</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Heise</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Baric</LastName><ForeName>Ralph S</ForeName><Initials>RS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI075297</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 AI081680</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32GM008719</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54AI080680</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54AI081680-01</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008719</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI075297</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011657" MajorTopicYN="N">Pulmonary Eosinophilia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21937658</ArticleId><ArticleId IdType="pii">JVI.06048-11</ArticleId><ArticleId IdType="doi">10.1128/JVI.06048-11</ArticleId><ArticleId IdType="pmc">PMC3209347</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jpn J Infect Dis. 2007 May;60(2-3):106-12</Citation><ArticleIdList><ArticleId IdType="pubmed">17515642</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Res. 2007 Jul;62(1):111-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17515829</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Jul;81(14):7410-23</Citation><ArticleIdList><ArticleId IdType="pubmed">17507479</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 Feb 20;24(8):1159-69</Citation><ArticleIdList><ArticleId IdType="pubmed">16213065</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3722-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16505353</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Pathol. 2006 May;59(5):468-76</Citation><ArticleIdList><ArticleId IdType="pubmed">16461566</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Aug;80(16):7918-28</Citation><ArticleIdList><ArticleId IdType="pubmed">16873249</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2006 Aug 1;351(2):466-75</Citation><ArticleIdList><ArticleId IdType="pubmed">16690096</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2006 Aug;12(8):905-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16862151</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Exp Med Biol. 2006;581:547-50</Citation><ArticleIdList><ArticleId IdType="pubmed">17037596</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation><ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Jan;81(2):548-57</Citation><ArticleIdList><ArticleId IdType="pubmed">17108024</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2006 Dec;3(12):e525</Citation><ArticleIdList><ArticleId IdType="pubmed">17194199</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12123-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17620608</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Aug;81(16):8692-706</Citation><ArticleIdList><ArticleId IdType="pubmed">17537853</ArticleId></ArticleIdList></Reference><Reference><Citation>Antivir Ther. 2007;12(7):1107-13</Citation><ArticleIdList><ArticleId IdType="pubmed">18018769</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2008 Apr;82(7):3220-35</Citation><ArticleIdList><ArticleId IdType="pubmed">18199635</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2008 Apr;133(1):45-62</Citation><ArticleIdList><ArticleId IdType="pubmed">17416434</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2008 Apr;133(1):20-32</Citation><ArticleIdList><ArticleId IdType="pubmed">17499378</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Aug 5;26(33):4267-75</Citation><ArticleIdList><ArticleId IdType="pubmed">18582997</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2008 Sep;89(Pt 9):2136-46</Citation><ArticleIdList><ArticleId IdType="pubmed">18753223</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Sep 15;26(39):4998-5003</Citation><ArticleIdList><ArticleId IdType="pubmed">18656518</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2008 Nov 1;181(9):6337-48</Citation><ArticleIdList><ArticleId IdType="pubmed">18941225</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2008 Nov 15;181(10):6692-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18981084</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Nov 25;26(50):6338-43</Citation><ArticleIdList><ArticleId IdType="pubmed">18824060</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19944-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19036930</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2009 Jan;15(1):34-41</Citation><ArticleIdList><ArticleId IdType="pubmed">19079256</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2009 Apr;83(7):3212-27</Citation><ArticleIdList><ArticleId IdType="pubmed">19176631</ArticleId></ArticleIdList></Reference><Reference><Citation>Toxicol Pathol. 2009 Feb;37(2):249-55</Citation><ArticleIdList><ArticleId IdType="pubmed">19181630</ArticleId></ArticleIdList></Reference><Reference><Citation>Inflamm Res. 2009 Jun;58(6):312-20</Citation><ArticleIdList><ArticleId IdType="pubmed">19234811</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2009 Jul;83(14):7062-74</Citation><ArticleIdList><ArticleId IdType="pubmed">19420084</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2009 Oct;5(10):e1000642</Citation><ArticleIdList><ArticleId IdType="pubmed">19888339</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Genet Evol. 2009 Dec;9(6):1185-96</Citation><ArticleIdList><ArticleId IdType="pubmed">19800030</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2010 Mar 30;399(1):120-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20110095</ArticleId></ArticleIdList></Reference><Reference><Citation>Viral Immunol. 2010 Oct;23(5):509-19</Citation><ArticleIdList><ArticleId IdType="pubmed">20883165</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol Sin. 2010 Feb;25(1):36-44</Citation><ArticleIdList><ArticleId IdType="pubmed">20960282</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Vaccine Immunol. 2010 Dec;17(12):1829-35</Citation><ArticleIdList><ArticleId IdType="pubmed">20876821</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2011 Jan;85(1):217-30</Citation><ArticleIdList><ArticleId IdType="pubmed">20980507</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Biol Int. 2011 May;35(5):467-74</Citation><ArticleIdList><ArticleId IdType="pubmed">20977431</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011;6(7):e21958</Citation><ArticleIdList><ArticleId IdType="pubmed">21755013</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2011 Jul;179(1):199-210</Citation><ArticleIdList><ArticleId IdType="pubmed">21703402</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2002 May 31;20 Suppl 3:S34-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12184362</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 May 24;361(9371):1761-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12781533</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Jun 4;289(21):2801-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12734147</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12995-3000</Citation><ArticleIdList><ArticleId IdType="pubmed">14569023</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Feb 13;303(5660):944-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14963300</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Mar 12;303(5664):1666-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14752165</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chem. 2004 Jun;50(6):988-95</Citation><ArticleIdList><ArticleId IdType="pubmed">15054081</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Immunol. 2004 Oct;16(10):1423-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15314040</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2004 Dec 10;325(2):445-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15530413</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2005 Feb 15;191(4):507-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15655773</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2430-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15695582</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Mar;79(6):3401-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15731234</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 May;79(9):5833-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15827197</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2005 May 9;23(25):3294-300</Citation><ArticleIdList><ArticleId IdType="pubmed">15837235</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2005 Oct;77(2):147-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16121363</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16169905</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Sep 30;309(5744):2154-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16195440</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Oct 28;310(5748):676-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 Jan 30;24(5):652-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16214268</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pathol. 2007 Jan;211(2):144-56</Citation><ArticleIdList><ArticleId IdType="pubmed">17200946</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Mar 8;25(12):2173-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17227689</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2007 Jan;3(1):e5</Citation><ArticleIdList><ArticleId IdType="pubmed">17222058</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001468 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001468 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:21937658
|texte= A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:21937658" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |